2020
Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
MACHÁČKOVÁ, Táňa, Karolína TRACHTOVÁ, Vladimír PROCHÁZKA, Tomáš GROLICH, Martina FARKAŠOVÁ et. al.Základní údaje
Originální název
Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
Autoři
MACHÁČKOVÁ, Táňa (203 Česká republika, domácí), Karolína TRACHTOVÁ (203 Česká republika, domácí), Vladimír PROCHÁZKA (203 Česká republika, domácí), Tomáš GROLICH (203 Česká republika, domácí), Martina FARKAŠOVÁ (703 Slovensko, domácí), Lukáš FIALA (203 Česká republika), Roman ŠEFR (203 Česká republika), Igor KISS (203 Česká republika), Matej SKROVINA (203 Česká republika), Michal DOSOUDIL (203 Česká republika), Ioana BERINDAN-NEAGOE (642 Rumunsko), Marek SVOBODA (203 Česká republika), Ondřej SLABÝ (203 Česká republika, garant, domácí) a Zdeněk KALA (203 Česká republika, domácí)
Vydání
CANCER GENOMICS & PROTEOMICS, ATHENS, INT INST ANTICANCER RESEARCH, 2020, 1109-6535
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Řecko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 4.069
Kód RIV
RIV/00216224:14740/20:00118648
Organizační jednotka
Středoevropský technologický institut
UT WoS
000530098500004
Klíčová slova anglicky
Rectal cancer; chemoradiotherapy; microRNA; prediction
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 10. 3. 2021 16:15, Mgr. Pavla Foltynová, Ph.D.
Anotace
V originále
Background/Aim: Rectal cancer accounts for approximately one-third of all colorectal cancers. Currently, the standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) with capecitabine or 5-fluorouracil followed by curative surgery. Unfortunately, only 20% of patients with LARC present complete pathological response after CRT, whereas in 20-40% cases the response is poor or absent. The aim of our study was to evaluate whether microRNAs (miRNAs) in tumor biopsy specimen have the potential to predict therapeutic response in LARC patients. Patients and Methods: In total 87 LARC patients treated by CRT were enrolled in our prospective study. To identify predictive miRNAs, we used small RNA sequencing in 40 tumor biopsy samples of LARC patients (20 responders, 20 non-responders) and qPCR validation of selected miRNA candidates. Results: In the discovery phase of the study, we identified 69 miRNAs to have significantly different expression between the group of responders (TRG 1,2) and a group of non-responders (TRG 4,5) to neoadjuvant CRT. Among these miRNAs, 48 showed a lower expression and 21 showed higher expression in tumor tissues from poorly responding LARC patients. Five miRNAs were selected for validation, but only miR-487a-3p was confirmed to have a significantly higher expression in the tumor biopsy specimens of non-responders to neoadjuvant CRT (p<0.0006, AUC=0.766). Gene Ontology (GO) clustering and pathway enrichment analysis of the miR-487a-3p mRNA targets, revealed potential mechanisms behind miR487a-3p roles in chemoradioresistance (e.g. TGF-beta signaling pathway, protein kinase activity, double-stranded DNA binding, or microRNAs in cancer). Conclusion: By combination of miRNA expression profiling and integrative computational biology we identified miR-487a-3p as a potential predictive biomarker of CRT response in LARC patients.
Návaznosti
NV16-31765A, projekt VaV |
|